Aradigm Corp. (NSDQ:ARDM) shares tumbled today after the company reported that the FDA denied its application for an inhaled drug designed to treat non-cystic fibrosis bronchiectasis patients with chronic lung infections.
The agency’s complete response letter reportedly highlighted an array of concerns with the initial application, including product quality and the company’s clinical data.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA wants more clinical data for Aradigm’s inhaled lung drug appeared first on MassDevice.